The Food and Drug Administration (FDA) has given Alnylam Pharmaceuticals the green light to relaunch clinical trials of its treatment for the bleeding disorder
hemophilia after pausing the studies after a patient death.
Not exact matches
In November, Denner helped facilitate the sale of
hemophilia drug maker Bioverativ, for $ 11.6 billion, to Sanofi, a little more than a year
after the company was spun out of Biogen, of which Denner is a director.
«
After one dose of gene therapy,
hemophilia B patients maintain near - normal levels of clotting factor.»
Years
after receiving a single dose of gene therapy, patients on the
hemophilia B trial continued to produce their own clotting factor from the normal transferred gene with minimal side effects.
And, in Arcadia, Fla., the family of three young brothers who were exposed to the aids virus while being treated for
hemophilia has been forced to leave the community
after fire gutted their home.